FMO1 and metabolic dysfunction-associated steatohepatitis: In GSE89632, a significant decrease in AMDHD1 and P4HA1 expression level and a significant increase in FMO1 and LPL expression level were observed in patients in the NASH group compared to the HC group (Fig. 6B).